The detection of significant immune reactivity in oncogene-addicted NSCLC, in contrast the conception of an absolute “immune desert,” suggests that well-aimed use of immunomodulators currently explored in various pre-clinical studies and clinical trials [37, 61] may also hold promise in EGFR- and ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.